The impact of corticosteroids on growth and bone health
T Mushtaq, S F Ahmed

An examination of current evidence

Gluocorticoids (GC) are important regulators of diverse physiological systems and are often used in the treatment of a number of chronic inflammatory, autoimmune, and neoplastic diseases. It is estimated that 10% of children may require some form of GC at some point in their childhood. Impairment of childhood growth with an approximate cortisone dose of 1.5 mg/kg/day was first described over 40 years ago; osteopenia in children receiving a prednisolone dose of less than 0.16 mg/kg/day has also been reported. The maintenance of growth and bone health is a complex process that can be influenced not only by drugs, but also by the nutritional status of the patient and the underlying disease process. The purpose of this review is to examine the current evidence for linking GC to adverse growth and bone health in childhood disorders that commonly require GC therapy.

PATHOPHYSIOLOGY

Loss of bone and deterioration in short term growth are dependent on the type and dose of GC and occur most prominently over the first six months of treatment. Although it is generally believed that GC affect trabecular bone more than cortical bone, a recent study of fractures in children following steroid exposure as part of acute lymphoblastic leukaemia (ALL) treatment showed a high incidence of cortical bone involvement, suggesting that the disease process may interact with GC usage in influencing site of bone loss.

GC have a suppressive effect on osteoblastogenesis in the bone marrow and promote the apoptosis of osteoblasts and osteocytes, thus leading to decreased bone formation. Accumulation of apoptotic osteocytes may also explain the so called “osteonecrosis”, also known as aseptic or avascular necrosis. There is some evidence to suggest that GC may also increase bone resorption by extending the lifespan of pre-existing osteoclasts. GC may also promote calcium loss through the kidneys and gut, and this negative calcium balance can itself lead to increased bone remodelling and osteoclastic activity due to secondary hyperparathyroidism.

High dose GC therapy can attenuate physiological growth hormone (GH) secretion via an increase in somatostatin tone, and the GH response to GH stimulation tests may be reversibly impaired in some cases of steroid exposure. However, GC induced growth failure may also be due to direct effects on the growth plate. Infusion of GC into the growth plate leads to a temporary reduction in the growth rate of that leg and may disrupt the growth plate vasculature. GC exposed chondrocytes show reduced proliferation rates and a reversible, prolonged resting period. In vitro studies suggest that local somatotrophic action of GH and IGF-1 may be affected by a number of different mechanisms, including alterations in the activity of the GH binding protein, down regulation of GH receptor expression and binding capacity, and a reduction in local IGF-1 production and activity.

GC may also impair the attainment of peak bone mass and delay growth through alterations in gonadal function at the level of the pituitary and through direct effects on the gonads. Studies in adults show that GC therapy may be associated with testosterone deficiency as well as reversible gonadotrophin deficiency. Levels of other sex steroids such as androstenedione and oestradiol may also be depressed due to adrenarche inactivity following chronic GC therapy. In addition, there is in vitro evidence suggesting that GC impair FSH action, thus reducing oestrogen secretion.

Figure 1 summarises the mechanisms of GC induced bone loss and growth retardation.

ASTHMA, ECZEMA, AND HAY FEVER

The increasing incidence and prevalence of childhood atopy and the more widespread use of inhaled steroid therapy for asthma prophylaxis probably accounts for the largest group of children who are chronically exposed to steroids. Oral GC therapy in asthma is associated with a delay in growth and puberty, and there is some evidence to suggest that final height may also be compromised. Systemic exposure to inhaled steroids may be higher with metered dose inhalers and dry powder devices where 80% of the drug is deposited in the oropharynx. Although earlier studies did not show a relation between inhaled steroids and growth, there is now good evidence in children with relatively mild asthma that inhaled steroids can temporally slow growth and alter bone and collagen turnover. The magnitude of this effect may be influenced by the dose delivery system as well as the systemic bioavailability of the inhaled steroid used. This effect may be most pronounced over the first few weeks of treatment. Long term studies are difficult due to a number of

Abbreviations: ALL, acute lymphoblastic leukaemia; DEXA, dual energy x ray absorptiometry; GC, glucocorticoid; GH, growth hormone; JIA, juvenile idiopathic arthritis
confounding factors including the plethora of drugs, delivery systems, compliance, and disease severity but there is no clear evidence that final height is compromised following inhaled GC therapy in children with asthma. Studies of bone mineral density in children with asthma have not shown any significant abnormality but have only concentrated on those children who are on relatively low doses of inhaled steroids. Some intranasal GC such as budesonide have a very high level of systemic absorption when applied directly to the nasal mucosa; short and intermediate term studies of children on intranasal steroids such as budesonide and beclomethasone also show a deterioration in growth velocity. Like asthma, there is some suggestion that the effects of these intranasal steroids may be dose dependent and that the newer forms of intranasal steroids such as mometasone furoate may not have these adverse growth effects. Assessment of short term growth during topical steroid treatment for eczema has also been studied, but the results have been inconclusive.

**INFLAMMATORY BOWEL DISEASE**

Longitudinal studies show that the growth velocities of children in the year preceding diagnosis are reduced; growth retardation frequently complicates the clinical course in children. There is an increased recognition of osteoporosis in adult patients with chronic inflammatory bowel disease. In children with inflammatory bowel disease, retardation of growth and skeletal maturation are widely reported and may be related to disease activity as well as to its treatment. Vertebral fractures have also been described in children with Crohn’s disease with a short or absent history of steroid usage. A cross sectional study of bone mineralisation using dual energy x ray absorptiometry (DEXA) showed evidence of osteopenia even when corrected for sex, height, weight, and puberty. In this study, the bone status was related to steroid usage but had no relation to disease activity. In a longitudinal study of 55 children, uncorrected total body mineral density standard deviation score correlated negatively to cumulative steroid dosage and positively to body mass index. A reduction in bone mineral density of the lumbar spine, femoral neck, and radius may be more prominent in children with Crohn’s disease and those children who are of a pubertal or post-pubertal age. The recent introduction of budesonide enemas for treatment of distal colitis has also been reported to be associated with suppression of markers of bone formation.

**RENAAL DISEASE**

Impaired linear growth is one of the major complications of childhood onset chronic renal insufficiency and its treatment. Final height may be less than the third centile in 50% of children who enter end stage renal failure in childhood. It is unclear whether such children who are on appropriate vitamin D supplements have a poorer bone mineralisation status. Children with a history of renal insufficiency who receive GC may grow more slowly, have a poorer bone mineralisation status, and may not respond satisfactorily to vitamin D replacement compared to those who do not receive GC. The prolonged use of GC is also associated with growth failure and reduced bone mineral density in other childhood chronic renal disease, such as nephrotic syndrome. Post-transplantation, the cumulative GC dosage may be inversely related to the change in relative height, but this finding is not universal. Interindividual differences in the handling of GC as assessed by area under the curve estimation rather than dose have shown a stronger association with adverse growth in post-transplantation patients. In nephrotic syndrome, it is not clear whether intermittent GC therapy over a number of years has an adverse effect on growth correlates with final height. Following transplantation, a given cumulative dose of GC has a lower inhibitory effect on growth velocity, without compromising graft function, when given on alternate days. Although alternate day GC may not adversely affect final height potential, it may still delay puberty and be associated with a delayed growth spurt. Substitution of GC with other immunosuppressants improves growth but leads to a higher rate of rejection. The effect of these newer agents on growth and bone health while reducing the need of GC are unclear. Alternative forms of GC, such as dexamethasone, appear to have fewer effects on growth and corticosteroid induced osteoporosis, but are not used in common practice.

**ARTHRITIS**

GC are widely used for treating chronic connective tissue diseases in children; as with other inflammatory conditions, there is considerable overlap between the inflammatory process and steroid induced effects on bone health. A failure to develop adequate bone mineralisation is virtually universal in children with juvenile idiopathic arthritis (JIA) and is characterised by a failure of bone formation, with a subsequent failure to undergo the normal increase in bone mass during puberty. The reduction in bone mineral density and bone mineral gain may be adverse as the child was on steroids. Other studies have not shown any statistical significance of the cumulative dose of corticosteroids on growth, although they did note a reduction in the growth velocity during the first year of treatment which was more apparent in the polyarticular group. It does appear that good control of disease activity in systemic onset JIA can be achieved by high dose alternate day prednisolone with minimal side effects. The use of high doses of oral steroids in autoimmune conditions is associated with a prompt decrease of bone formation and collagen synthesis, without any significant changes in bone resorption; however, these negative effects seem to revert after lowering GC dosage.

**ACUTE LYMPHOBLASTIC LEUKAEMIA**

GC have been a mainstay of the therapy for childhood ALL. Dexamethasone is now replacing prednisolone as the drug of choice because of its greater lymphocytoxicity and higher CNS penetration. Recent studies have shown that bone mineralisation status as assessed by bone mineral density, corrected as well as uncorrected for body size, may be adversely affected immediately after completion of treatment. The fracture incidence during leukaemia treatment has been reported to be as high as 39%; this has been recently confirmed by Strauss et al who have shown a five year cumulative incidence of 28% for fractures and 7% for osteonecrosis, with a median follow up of over seven years. The median time from diagnosis to first fracture was 15 months and most occurred within two years of diagnosis. Older age, pubertal age, the male sex, and dexamethasone have been shown to be independent risk factors for fractures and reduced bone mineralisation. Previous studies by our group have shown alterations in bone turnover and short term growth of children during leukaemia treatment; these changes were most marked during periods of intensive chemotherapy and high dose systemic glucocorticoid administration. More recently, we have also reported that the biological potency of dexamethasone in suppressing growth may be 18 times higher than that of prednisolone.
immunomodulatory agents that may also have bone adverse effects greatly increase the risks posed to the growth and bone health of the child on chronic GC therapy.

The clinical effects on bone health can be divided into those occurring in the short term (fractures and avascular necrosis) and those that may occur over the longer term—that is, increased predisposition for osteoporosis and skeletal deformity. Current studies and clinical observations suggest that children who received prolonged GC therapy (for more than three months) have a higher incidence of fractures during therapy. For adults, the Royal College of Physicians has issued guidelines on indications for assessing and managing bone health. In the absence of any clear guidelines for children, it would seem prudent to monitor susceptible children carefully with regular review of bone scans, radiographs, and metabolic bone disease (including calcium and vitamin D status), anthropometry (including sitting height), pubertal status, and assessment of bone mineralisation status. Bone mineral status can be assessed by a number of methods and DEXA is by far the most popular method. Unlike adults where a single assessment of bone mineral density by DEXA can predict likelihood of fracture in age related osteoporosis, this relation is not so clear in children with GC induced osteoporosis. Children at risk of GC induced osteoporosis and those displaying growth failure should therefore have serial bone mineral density assessment to assess a change in status; results need to be carefully interpreted in relation to their sex, age, height, and weight, as well as their disease and its treatment. Current studies of long term follow up of children treated with chemotherapy only regimens for ALL do not show disturbances in final height or bone mineral status, and there are no data to support or refute the claim that prolonged GC therapy in childhood may lead to early osteoporosis in adulthood. Skeletal disproportion has been reported as a possible long term effect of ALL chemotherapy; it is not clear whether this phenomenon of skeletal disproportion is observed in other groups of children requiring chronic GC therapy. In the absence of any convincing evidence for or against long term osteopenia, it would, again, seem prudent to consider assessing growth and bone mineral status in all patients with a past history of prolonged GC exposure when they reach the end of their second decade and should have acquired peak bone mass. Failure to acquire peak bone mass should prompt longer term monitoring.

Prevention of GC induced growth retardation and adverse bone health could be addressed in a number of cases by judicious use of GC therapy coupled with improved nutrition and promotion of weight bearing activities. In addition, alternate day GC regimens and consideration of GC sparing drugs at an earlier stage than before may be possible preventive measures but need further evaluation. For reasons mentioned earlier, calcium and vitamin D supplementation is generally recommended in patients on GC therapy, although there is little objective clinical evidence to suggest that this practice prevents GC induced osteoporosis in adults or children. As hypogonadism may contribute both to poor growth and impaired bone mineral acquisition, addressing hypogonadism in pubertal children on GC therapy should be an important consideration. Recent studies show that recombinant GH treatment may be of benefit in halting the growth retardation and bone loss observed in children on chronic GC therapy. In children, the role of the antiresorptive group of drugs, bisphosphonates has been mostly studied in the field of osteogenesis imperfecta where their use is associated with a reduction in the frequency of fractures, improved bone mass, and mobility. Bisphosphonate therapy is now used regularly in adults for prevention and treatment of glucocorticoid induced osteoporosis and needs to be carefully evaluated in the paediatric setting. Acute vertebral fractures can be a debilitating condition that may be associated with a prolonged period of immobility during which the patient may become increasingly susceptible to further fractures. An early resumption of aerobic as well as weight bearing activity, with good analgesic control will require the support of a child oriented physiotherapist as well as the family. Current and future efforts in the fields of glucocorticoid resistance (GC-R) and tumour necrosis factor (TNF) polymorphisms may contribute to our understanding of GC induced osteoporosis and glucocorticoid induced growth retardation. It will be important to study the relationship between GC-R and nutrition, as well as the relationship between GC-R and childhood cancer outcome. Additionally, recombinant GH and a novel PTH fragment will be important tools in the management of GC induced osteoporosis and glucocorticoid induced growth retardation.

Skeletal disproportion has been reported as a possible long term effect of ALL chemotherapy; it is not clear whether this phenomenon of skeletal disproportion is observed in other groups of children requiring chronic GC therapy. In the absence of any convincing evidence for or against long term osteopenia, it would, again, seem prudent to consider assessing growth and bone mineral status in all patients with a past history of prolonged GC exposure when they reach the end of their second decade and should have acquired peak bone mass. Failure to acquire peak bone mass should prompt longer term monitoring.

References


Authors’ affiliations

T Mushthaq, Dept of Integrative Biology, Roslin Institute, Edinburgh, UK
S F Ahmed, Dept of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
Correspondence to: Dr S F Ahmed, Dept of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ, UK; gc.l1258@clinmed.gla.ac.uk

REFERENCES


Authors’ affiliations

T Mushthaq, Dept of Integrative Biology, Roslin Institute, Edinburgh, UK
S F Ahmed, Dept of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
Correspondence to: Dr S F Ahmed, Dept of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ, UK; gc.l1258@clinmed.gla.ac.uk

REFERENCES